Tri-Antigenic Hepatitis B Vaccine Elicits Significant Immunity
Kevin Kunzmann is the managing editor for Contagion, as well as its sister publication HCPLive. Prior to joining parent company MJH Life Sciences in 2017, he worked as a health care and government reporter for The Pocono Record, and as a freelance writer for NJ Advance Media, The Express-Times, The Daily Journal, and more. He graduated from Rowan University with a degree in journalism in 2015. In his spare time, he enjoys reading, cooking, running his dog, and complaining about the Mets. Follow him on Twitter @NotADoctorKevin or email him at [email protected]
New head-to-head phase 3 data show a promising potential new HBV vaccine may join the market in the near future.
A pair of phase 3 head-to-head trials found that tri-antigenic hepatitis B virus (HBV) vaccine (TAV) is capable of faster anti-hepatitis B titers versus mono-antigenic HBV vaccine (MAV) across all observed patient populations.
The summarization of findings from the CONSTANT and PROTECT trials, presented at IDWeek 2020, found the investigative TAV agent Sci-B-Vac from VBI Vaccines could provide up to eight-fold greater titers than standard MAV prophylaxes, and could potentially better cement global population prevention of HBV.
Now, the company intends to submit application materials to the US Food and Drug Administration (FDA) based on the merit of these findings. Currently, 2 billion people worldwide have or previously had HBV infection—indicating a need for more and greater vaccine options.
In an interview with Contagion® during IDWeek, presenting study author Joanne Langley, MD, Professor of Pediatrics at the Canadian Center for Vaccinology, Dalhousie University, discussed the importance of improved prevention of HBV.
“There still is a huge population that has never had the chance to be immunized against hepatitis B: adults who didn’t benefit from children’s programs, or whose immunogenicity is reduced because they don’t respond as we like to currently available vaccines,” she explained.
Langley went on to share details and significant outcomes from the IDWeek poster, which compared the couple of head-to-head phase 3 assessments of Sci-B-Vac versus MAV vaccines.
Listen to the full interview with Langley in the video above.
The poster, “Higher hepatitis B antibody titres induced in all adults vaccinated with a tri-antigenic hepatitis B (HBV) vaccine, compared to a mono-antigenic HBV vaccine: results from two pivotal phase 3 double-blind, randomized studies (PROTECT and CONSTANT),” was presented at IDWeek 2020.